Identification of CYP3A4 as the principal enzyme catalyzing mifepristone (RU 486) oxidation in human liver microsomes

Biochemical Pharmacology

Volumn 52, Issue 5, 1996, Pages 753-761

  Jang, Graham R ^a   Wrighton, Steven A ^b   Benet, Leslie Z ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

CYP3A4; cytochrome P450; demethylation; human liver microsomes; hydroxylation; mifepristone

Indexed keywords

CYTOCHROME P450 ISOENZYME; ETHINYLESTRADIOL; GESTODENE; MIDAZOLAM; MIFEPRISTONE; PROGESTERONE; TROLEANDOMYCIN;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METABOLISM; PRIORITY JOURNAL;

EID: 0030582402     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(96)00357-7     Document Type: Article

References (52)

1. 1. Ulmann A, Teutsch G and Philibert D, RU 486. Sci Am 262: 42-48, 1990.
2. 2. Heikinheimo O, Antiprogesterone steroid RU486. Pharmacokinetics and receptor binding in humans. Acta Obstet Gynecol Scand 69: 357-358, 1990.
3. 3. Donaldson M, Dorflinger L, Brown SS and Benet LZ (Eds.), Clinical Applications of Mifepristone (RU 486) and Other Antiprogestins. National Academy Press, Washington, DC, 1993.
4. 4. Glasier A and Baird DT, Post-ovulatory contraception. Baillieres Clin Obstet Gynaecol 4: 283-291, 1990.
5. 5. Webb AMC, Russell J and Elstein M, Comparison of Yuzpe regimen, danazol, and mifepristone (RU486) in oral post-coital contraception. BMJ 305: 927-931, 1992.
6. 6. Batista MC, Cartledge TP, Zellmer AW, Merino MJ, Axiotis C, Loriaux DL and Nieman LK, Delayed endometrial maturation induced by daily administration of the antiprogestin RU 486: A potential new contraceptive strategy. Am J Obstet Gynecol 167: 60-65, 1992.
7. 7. Greene KE, Kettel LM and Yen SSC, Interruption of endometrial maturation without hormonal changes by an antiprogesterone during the first half of luteal phase of the menstrual cycle: A contraceptive potential. Fertil Steril 58: 338-343, 1992.
8. 8. Schneider MR, Michna H, Nishino Y and el Etreby MF, Antitumor activity and mechanism of action of different antiprogestins in experimental breast cancer models. J Steroid Biochem Mol Biol 37: 783-787, 1990.
9. 9. Bakker GH, Setyono-Han B, Portengen H, De Jong FH, Foekens JA and Klijn JG, Treatment of breast cancer with different antiprogestins: Preclinical and clinical studies. J Steroid Biochem Mol Biol 37: 789-794, 1990.
10. 10. Lin MF, Kawachi MH, Stallcup MR, Grunberg SM and Lin FF, Growth inhibition of androgen-insensitive human prostate carcinoma cells by a 19-norsteroid derivative agent, mifepristone. Prostate 26: 194-204, 1995.
11. 11. Grunberg SM, Weiss MH, Spitz IM, Ahmadi J, Sadun A, Russell CA, Lucci L and Stevenson LL, Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J Neurosurg 74: 861-866, 1991.
12. 12. Lamberts SW, Tanghe HL, Avezaat CJ, Braakman R, Wijngaarde R, Koper JW and de Jong H, Mifepristone (RU 486) treatment of meningiomas. J Neurol Neurosurg Psychiatry 55: 486-490, 1992.
13. 13. Kettel LM, Murphy AA, Morales AJ and Yen SS, Clinical efficacy of the antiprogesterone RU486 in the treatment of endometriosis and uterine fibroids. Hum Reprod 9(Suppl 1): 116-120, 1994.
14. 14. Lecureur V, Fardel O and Guillouzo A, The antiprogestatin drug RU 486 potentiates doxorubicin cytotoxicity in multidrug resistant cells through inhibition of P-glycoprotein function. FEBS Lett 355: 187-191, 1994.
15. 15. Gruol DJ, Zee MC, Trotter J and Bourgeois S, Reversal of multidrug resistance by RU 486. Cancer Res 54: 3088-3091, 1994.
16. 16. van der Lely A, Foeken K, van der Mast R and Lamberts SW, Rapid reversal of acute psychosis in the Cushing syndrome with the cortisol-receptor antagonist mifepristone (RU 486). Ann Intern Med 114: 143-144, 1991.
17. 17. Waxman DJ, Attisano C, Guengerich FP and Lapenson DP, Human liver microsomal steroid metabolism: Identification of the major microsomal steroid hormone 6β-hydroxylase cytochrome P-450 enzyme. Arch Biochem Biophys 263: 424-436, 1988.
18. 18. Waxman DJ, Lapenson DP, Aoyama T, Gelboin HV, Gonzalez FJ and Korzekwa K, Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. Arch Biochem Biophys 290: 160-166, 1991.
19. 19. Guengerich FP, Martin MV, Beaune PH, Kremers P, Wolff T and Waxman DJ, Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 261: 5051-5060, 1986.
20. 20. Kronbach T, Fischer V and Meyer UA, Cyclosporine metabolism in human liver: Identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 43: 630-635, 1988.
21. 21. Sattler M, Guengerich FP, Yun C-H, Christians U and Sewing K-F, Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 20: 753-761, 1992.
22. 22. Kronbach T, Mathys D, Umeno M, Gonzalez FJ and Meyer UA, Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 36: 89-96, 1989.
23. 23. Imaoka S, Enomoto K, Oda Y, Asada A, Fujimori M, Shimada T, Fujita S, Guengerich FP and Funae Y, Lidocaine metabolism by human cytochrome P-450s purified from hepatic microsomes: Comparison of those with rat hepatic cytochrome P-450s. J Pharmacol Exp Ther 255: 1385-1391, 1990.
24. 24. Trivier J-M, Libetsa C, Belloc C and Lhermitte M, Amiodarone N-deethylation in human liver microsomes: involvement of cytochrome P450 3A enzymes (first report). Life Sci 52: PL91-PL96, 1993.
25. 25. Fabre G, Julian B, Saint-Aubert B, Joyeux H and Berger Y, Evidence for CYP3A-mediated N-deethylation of amiodarone in human liver microsomal fractions. Drug Metab Dispos 21: 978-985, 1993.
26. 26. Guengerich FP, Muller ED and Blair IA, Oxidation of quinidine by human liver cytochrome P-450. Mol Pharmacol 30: 287-295, 1986.
27. 27. Harris JW, Rahman A, Kim BR, Guengerich FP and Collins JM, Metabolism of taxol by human hepatic microsomes and liver slices: Participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res 54: 4026-4035, 1994.
28. 28. Relling MV, Evans R, Dass C, Desiderio DM and Nemec J, Human cytochrome P450 metabolism of teniposide and etoposide. J Pharmacol Exp Ther 261: 491-496, 1992.
29. 29. Zhou-Pan X-R, Sérée E, Zhou X-J, Placidi M, Maurel P, Barra Y and Rahmani R, Involvement of human liver cytochrome P450 3A in vinblastine metabolism: Drug interactions. Cancer Res 53: 5121-5126, 1993.
30. 30. Zhou X-J, Zhou-Pan X-R, Gauthier T, Placidi M, Maurel P and Rahmani R, Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Metabolic drug interactions. Biochem Pharmacol 45: 853-861, 1993.
31. 31. Chasserot-Golaz S, Parcollet P and Beck G, Interrelationship between RU38486 and the P450 activities in rat liver. J Steroid Biochem 34: 473-478, 1989.
32. 32. Chasserot-Golaz S, Ribeiro V, Genot G, Lechner MC and Beck G, The steroid antagonist RU38486 is metabolized by the liver microsomal P450 mono-oxygenases. Biochem Biophys Res Commun 167: 1271-1278, 1990.
33. 33. Shimada T, Yamazaki H, Mimura M, Inui Y and Guengerich FP, Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270: 414-423, 1994.
34. 34. Wrighton SA and Stevens JC, The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 22: 1-21, 1992.
35. 35. Chasserot-Golaz S and Beck G, How the potency of the steroid RU486 is related to P450 activities induced by dexamethasone and phenobarbital in rat hepatoma cells. J Steroid Biochem Mol Biol 41: 653-657, 1992.
36. 36. Chasserot-Golaz S, Beck G and Venetianer A, Biotransformation of 17β-hydroxy-11β-(4-dimethylaminophenyl)17a-1-propynyl-estra-4,9-dien-3-one (RU486) in rat hepatoma variants. Biochem Pharmacol 46: 2100-2103, 1993.
37. 37. Guengerich FP, Analysis and characterization of enzymes. In: Principles and Methods of Toxicology (Ed. Haves AW), 2nd Edn, pp. 777-814. Raven Press, New York, 1989.
38. 38. Omura T and Sato R, The carbon monooxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239: 2370-2378, 1964.
39. 39. Wrighton SA, VandenBranden M, Stevens JC, Shipley LA, Ring BJ, Rettie AE and Cashman JR, In vitro methods for assessing human hepatic drug metabolism: Their use in drug development [published erratum appears in Drug Metab Rev 26: 483, 1994]. Drug Metab Rev 25: 453-484, 1993.
40. 40. Gorski JC, Jones DR, Wrighton SA and Hall SD, Characterization of dextromethorphan N-demethylation by human liver microsomes. Contribution of the cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 48: 173-182, 1994.
41. 41. Hall SD, Hamman MA, Rettie AE, Wienkers LC, Trager WF, VandenBranden M and Wrighton SA, Relationships between the levels of cytochrome P4502C9 and its prototypic catalytic activities in human liver microsomes. Drug Metab Dispos 22: 975-978, 1994.
42. 42. Heikinheimo O, Ylikorkala O, Turpeinen U and Lahteenmaki P, Pharmacokinetics of the antiprogesterone RU 486: No correlation to clinical performance of RU 486. AcM Endocrinol (Copenh) 123: 298-304, 1990.
43. 43. Newton DJ, Wang RW and Lu AY, Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23: 154-158, 1995.
44. 44. Shou M, Grogan J, Mancewicz JA, Krausz KW, Gonzalez FJ, Gelboin HV and Korzekwa KR, Activation of CYP3A4: Evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry 33: 6450-6455, 1994.
45. 45. Yun CH, Wood M, Wood AJ and Guengerich FP, Identification of the pharmacogenetic determinants of alfentanil metabolism: Cytochrome P-450 3A4. An explanation of the variable elimination clearance [see comments]. Anesthesiology 77: 467-474, 1992.
46. 46. Chang TK, Gonzalez FJ and Waxman DJ, Evaluation of triacetyloleandomycin, α-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch Biochem Biophys 311: 437-442, 1994.
47. 47. Wrighton SA, Ring BJ, Watkins PB and VandenBranden M, Identification of a polymorphically expressed member of the human cytochrome P-450III family. Mol Pharmacol 36: 97-105, 1989.
48. 48. Wrighton SA, Brian WR, Sari MA, Iwasaki M, Guengerich FP, Raucy JL, Molowa DT and VandenBranden M, Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol 38: 207-213, 1990.
49. 49. Gorski JC, Hall SD, Jones DR, VandenBranden M and Wrighton SA, Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 47: 1643-1653, 1994.
50. 50. Schuetz JD, Kauma S and Guzelian PS, Identification of the fetal liver cytochrome CYP3A7 in human endometrium and placenta. J Clin Invest 92: 1018-1024, 1993.
51. 51. Kitada M, Kamataki T, Itahashi K, Rikihisa T, Kato R and Kanakubo Y, Purification and properties of cytochrome P-450 from homogenates of human fetal livers. Arch Biochem Biophys 241: 275-280, 1985.
52. 52. Kitada M, Kamataki T, Itahashi K, Rikihisa T and Kanakubo Y, P-450 HFLa, a form of cytochrome P-450 purified from human fetal livers, is the 16α-hydroxylase of dehydroepiandrosterone 3-sulfate. J Biol Chem 262: 13534-13537, 1987.